PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc., a global leader in biosimulation by 2019 revenue, today announced that on December 15, 2020, it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share. The closing includes 4,358,250 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold 14,630,000 shares of its common stock, and certain selling stockholders sold 18,783,250 shares of common stock in the offering. The gross proceeds to Certara from the offering were approximately $336.5 million, before deducting the underwriting discount and offering expenses. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Shares of Certara’s common stock began trading on The Nasdaq Global Select Market on December 11, 2020, under the ticker symbol “CERT.”

About Certara

Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.